Business Context and Reporting Period
Company: ClearOne, Inc. (Nasdaq: CLRO)
Filing Type: Form 8-K (Current Report)
Report Date: July 6, 2026
Event Date: July 1, 2026
Context: The Company entered into an Agreement and Plan of Merger to acquire Cortigent, Inc. from Vivani Medical, Inc. ("Vivani").
Key Financial Metrics and Transaction Terms
This filing details a material definitive agreement rather than periodic financial results. Key transaction metrics include:
- Merger Consideration: Vivani will receive 12,500,000 shares of ClearOne common stock.
- Financing Plan: ClearOne intends to raise between $10,000,000 and $15,000,000 via a Form S-1 registration statement (units of common stock and warrants).
- Equity Issuance: Up to 855,000 shares may be issued to financial advisors; up to 1,400,000 stock options may be granted to Cortigent affiliates.
- Lock-up Restrictions: 50% of Consideration Shares are locked for one year; the remaining 50% for two years.
- Equity Moratorium: A 12-month moratorium on equity issuance applies post-closing, subject to exceptions.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for ClearOne or Cortigent.
Material Changes and Governance
The transaction represents a significant change in corporate structure and leadership:
- Post-Closing Board: Five members including Adam Mendelsohn (Chairman), Jonathan Adams, John Bowers, Linda Szyper, and Eric Robinson (Audit Committee Chair).
- Post-Closing Officers: Jonathan Adams (President & CEO), Ed Sedo (CFO), and Rachel Evans (Corporate Secretary).
- Voting Support: Stockholders holding 50.1% of ClearOne stock and Vivani have entered into voting support agreements to facilitate the transaction.
- Termination Date: The agreement may be terminated if not consummated within 180 days of July 1, 2026, unless extended.
Guidance, Risks, and Conditions
Conditions to Closing:
- Stockholder approval from both ClearOne and Vivani.
- Successful completion of the $10M-$15M Financing.
- Continued listing of ClearOne on The Nasdaq Capital Market.
- Effectiveness of the Form S-1 registration statement.
Risks and Contingencies:
- The transaction is contingent on regulatory approvals and financing success.
- Failure to meet the 180-day deadline could result in termination.
- Post-closing equity issuance is restricted for 12 months.
Investor Verification Checklist
- Verify the status of the Form S-1 registration statement for the $10M-$15M financing.
- Confirm stockholder approval outcomes for both ClearOne and Vivani.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific termination rights and indemnification clauses.
- Monitor the 180-day timeline for transaction consummation.
- Assess the impact of the 12-month equity moratorium on future capital raising capabilities.